<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;ff=20240821180851
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;ff=20240821180851" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 21 Aug 2024 22:08:52 +0000</lastbuilddate>
<pubDate>Wed, 21 Aug 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Tombstone Pattern Electrocardiogram in a Young Woman</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39167414/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821180851&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Aug 21. doi: 10.1001/jamacardio.2024.2537. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39167414/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821180851&v=2.18.0.post9+e462414">39167414</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2537>10.1001/jamacardio.2024.2537</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39167414</guid>
<pubDate>Wed, 21 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Yun Chen</dc:creator>
<dc:creator>Ping Ge</dc:creator>
<dc:creator>Xiao-Feng Zhuang</dc:creator>
<dc:date>2024-08-21</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Tombstone Pattern Electrocardiogram in a Young Woman</dc:title>
<dc:identifier>pmid:39167414</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2537</dc:identifier>
</item>
<item>
<title>Redefining Cardiac Involvement and Targets of Treatment in Systemic Immunoglobulin AL Amyloidosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39167388/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821180851&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: This study found that ECV mapping, in systemic AL amyloidosis, is an independent predictor of prognosis, can help define the hematological response associated with better long-term outcomes for each patient and potentially inform treatment strategies.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Aug 21. doi: 10.1001/jamacardio.2024.2555. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Cardiac amyloid infiltration is the key determinant of survival in systemic light-chain (AL) amyloidosis. Current guidelines recommend early switching therapy in patients with a nonoptimal or suboptimal response regardless of the extent of cardiac amyloid infiltration.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To assess the differences between serum biomarkers, echocardiography, and cardiovascular magnetic resonance (CMR) with extracellular volume (ECV) mapping in characterizing cardiac amyloid, the independent prognostic role of these approaches, and the role of ECV mapping to guide treatment strategies.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: Consecutive patients newly diagnosed with systemic AL amyloidosis (2015-2021) underwent echocardiography, cardiac biomarkers, and CMR with ECV mapping at diagnosis. Data were analyzed from January to June 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcomes of the study were all-cause mortality and hematological response as defined according to validated criteria: no response (NR), partial response (PR), very good partial response (VGPR), and complete response (CR). Secondary outcomes were the depth and speed of hematological response and overall survival according to ECV.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 560 patients with AL amyloidosis, the median (IQR) age was 68 years (59-74 years); 346 patients were male (61.8%) and 214 female (38.2%). Over a median (IQR) 40.5 months 9-58 months), ECV was independently associated with mortality. In the landmark analysis at 1 month, long-term survival was independent of the achieved hematological response in ECV less than 0.30% and ECV of 0.31% to 0.40%, while it was dependent on the depth of the hematological response in ECV greater than 0.40%. In the landmark analysis at 6 months, survival was independent of the achieved hematological response in ECV less than 0.30% and dependent on achieving at least PR in ECV of 0.31% to 0.40%. Survival was dependent on achieving CR in ECV of 0.41% to 0.50% and ECV greater than 0.50%. Achieving a deep hematological response at 1 month was associated with better survival compared with 6 months in patients with ECV greater than 0.40% but not with ECV less than 0.40%.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: This study found that ECV mapping, in systemic AL amyloidosis, is an independent predictor of prognosis, can help define the hematological response associated with better long-term outcomes for each patient and potentially inform treatment strategies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39167388/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821180851&v=2.18.0.post9+e462414">39167388</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2555>10.1001/jamacardio.2024.2555</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39167388</guid>
<pubDate>Wed, 21 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Aldostefano Porcari</dc:creator>
<dc:creator>Ambra Masi</dc:creator>
<dc:creator>Ana Martinez-Naharro</dc:creator>
<dc:creator>Yousuf Razvi</dc:creator>
<dc:creator>Rishi Patel</dc:creator>
<dc:creator>Adam Ioannou</dc:creator>
<dc:creator>Muhammad U Rauf</dc:creator>
<dc:creator>Giulio Sinigiani</dc:creator>
<dc:creator>Brendan Wisniowski</dc:creator>
<dc:creator>Stefano Filisetti</dc:creator>
<dc:creator>Jasmine Currie-Cathey</dc:creator>
<dc:creator>Sophie O'Beara</dc:creator>
<dc:creator>Tushar Kotecha</dc:creator>
<dc:creator>Dan Knight</dc:creator>
<dc:creator>James C Moon</dc:creator>
<dc:creator>Gianfranco Sinagra</dc:creator>
<dc:creator>Ruta Virsinskaite</dc:creator>
<dc:creator>Janet Gilbertson</dc:creator>
<dc:creator>Lucia Venneri</dc:creator>
<dc:creator>Aviva Petrie</dc:creator>
<dc:creator>Helen Lachmann</dc:creator>
<dc:creator>Carol Whelan</dc:creator>
<dc:creator>Peter Kellman</dc:creator>
<dc:creator>Sriram Ravichandran</dc:creator>
<dc:creator>Oliver Cohen</dc:creator>
<dc:creator>Shameem Mahmood</dc:creator>
<dc:creator>Charlotte Manisty</dc:creator>
<dc:creator>Philip N Hawkins</dc:creator>
<dc:creator>Julian D Gillmore</dc:creator>
<dc:creator>Ashutosh D Wechalekar</dc:creator>
<dc:creator>Marianna Fontana</dc:creator>
<dc:date>2024-08-21</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Redefining Cardiac Involvement and Targets of Treatment in Systemic Immunoglobulin AL Amyloidosis</dc:title>
<dc:identifier>pmid:39167388</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2555</dc:identifier>
</item>
<item>
<title>Reporting Primary Language in Cardiology Clinical Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39167373/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821180851&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Aug 21. doi: 10.1001/jamacardio.2024.2483. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39167373/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821180851&v=2.18.0.post9+e462414">39167373</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2483>10.1001/jamacardio.2024.2483</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39167373</guid>
<pubDate>Wed, 21 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Zara Latif</dc:creator>
<dc:creator>Vanessa Blumer</dc:creator>
<dc:creator>Ersilia M DeFilippis</dc:creator>
<dc:date>2024-08-21</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Reporting Primary Language in Cardiology Clinical Trials</dc:title>
<dc:identifier>pmid:39167373</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2483</dc:identifier>
</item>
<item>
<title>The challenge of interpreting cardiac adaptation to exercise: the importance of picking up the training history</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39167078/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821180851&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 21:ehae535. doi: 10.1093/eurheartj/ehae535. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39167078/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821180851&v=2.18.0.post9+e462414">39167078</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae535>10.1093/eurheartj/ehae535</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39167078</guid>
<pubDate>Wed, 21 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Viviana Maestrini</dc:creator>
<dc:creator>Maria Rosaria Squeo</dc:creator>
<dc:creator>Sara Monosilio</dc:creator>
<dc:date>2024-08-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The challenge of interpreting cardiac adaptation to exercise: the importance of picking up the training history</dc:title>
<dc:identifier>pmid:39167078</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae535</dc:identifier>
</item>
<item>
<title>Dapagliflozin, peptide YY, and weight loss in heart failure with preserved ejection fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39167062/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821180851&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 21:ehae534. doi: 10.1093/eurheartj/ehae534. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39167062/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821180851&v=2.18.0.post9+e462414">39167062</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae534>10.1093/eurheartj/ehae534</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39167062</guid>
<pubDate>Wed, 21 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Yogesh N V Reddy</dc:creator>
<dc:creator>Vojtech Melenovsky</dc:creator>
<dc:creator>Aneesh K Asokan</dc:creator>
<dc:creator>Martin Haluzik</dc:creator>
<dc:creator>Rickey E Carter</dc:creator>
<dc:creator>Sreekumaran Nair</dc:creator>
<dc:creator>Michael D Jensen</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:date>2024-08-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Dapagliflozin, peptide YY, and weight loss in heart failure with preserved ejection fraction</dc:title>
<dc:identifier>pmid:39167062</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae534</dc:identifier>
</item>
<item>
<title>Targeting the I&lt;sub>;Ks&lt;/sub>; Channel PKA Phosphorylation Axis to Restore Its Function in High-Risk LQT1 Variants</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39166328/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821180851&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our findings not only elucidate the molecular mechanism of PKA-dependent I(Ks) channel phosphorylation but also provide an effective antiarrhythmic strategy for patients with high-risk LQT1 variants.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Aug 21. doi: 10.1161/CIRCRESAHA.124.325009. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The KCNQ1+KCNE1 (I<sub>Ks</sub>) potassium channel plays a crucial role in cardiac adaptation to stress, in which β-adrenergic stimulation phosphorylates the I<sub>Ks</sub> channel through the cyclic adenosine monophosphate (cAMP)/PKA (protein kinase A) pathway. Phosphorylation increases the channel current and accelerates repolarization to adapt to an increased heart rate. Variants in KCNQ1 can cause long-QT syndrome type 1 (LQT1), and those with defective cAMP effects predispose patients to the highest risk of cardiac arrest and sudden death. However, the molecular connection between I<sub>Ks</sub> channel phosphorylation and channel function, as well as why high-risk LQT1 mutations lose cAMP sensitivity, remain unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Regular patch clamp and voltage clamp fluorometry techniques were utilized to record pore opening and voltage sensor movement of wild-type and mutant KCNQ1/I<sub>Ks</sub> channels. The clinical phenotypic penetrance of each LQT1 mutation was analyzed as a metric for assessing their clinical risk. The patient-specific-induced pluripotent stem-cell model was used to test mechanistic findings in physiological conditions.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: By systematically elucidating mechanisms of a series of LQT1 variants that lack cAMP sensitivity, we identified molecular determinants of I<sub>Ks</sub> channel regulation by phosphorylation. These key residues are distributed across the N-terminus of KCNQ1 extending to the central pore region of I<sub>Ks</sub>. We refer to this pattern as the I<sub>Ks</sub> channel PKA phosphorylation axis. Next, by examining LQT1 variants from clinical databases containing 10 579 LQT1 carriers, we found that the distribution of the most high-penetrance LQT1 variants extends across the I<sub>Ks</sub> channel PKA phosphorylation axis, demonstrating its clinical relevance. Furthermore, we found that a small molecule, ML277, which binds at the center of the phosphorylation axis, rescues the defective cAMP effects of multiple high-risk LQT1 variants. This finding was then tested in high-risk patient-specific induced pluripotent stem cell-derived cardiomyocytes, where ML277 remarkably alleviates the beating abnormalities.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings not only elucidate the molecular mechanism of PKA-dependent I<sub>Ks</sub> channel phosphorylation but also provide an effective antiarrhythmic strategy for patients with high-risk LQT1 variants.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39166328/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821180851&v=2.18.0.post9+e462414">39166328</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325009>10.1161/CIRCRESAHA.124.325009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39166328</guid>
<pubDate>Wed, 21 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Ling Zhong</dc:creator>
<dc:creator>Zhenzhen Yan</dc:creator>
<dc:creator>Dexiang Jiang</dc:creator>
<dc:creator>Kuo-Chan Weng</dc:creator>
<dc:creator>Yue Ouyang</dc:creator>
<dc:creator>Hangyu Zhang</dc:creator>
<dc:creator>Xiaoqing Lin</dc:creator>
<dc:creator>Chenxin Xiao</dc:creator>
<dc:creator>Huaiyu Yang</dc:creator>
<dc:creator>Jing Yao</dc:creator>
<dc:creator>Xinjiang Kang</dc:creator>
<dc:creator>Changhe Wang</dc:creator>
<dc:creator>Chen Huang</dc:creator>
<dc:creator>Bing Shen</dc:creator>
<dc:creator>Sookja Kim Chung</dc:creator>
<dc:creator>Zhi-Hong Jiang</dc:creator>
<dc:creator>Wandi Zhu</dc:creator>
<dc:creator>Erwin Neher</dc:creator>
<dc:creator>Jonathan R Silva</dc:creator>
<dc:creator>Panpan Hou</dc:creator>
<dc:date>2024-08-21</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Targeting the I&lt;sub>;Ks&lt;/sub>; Channel PKA Phosphorylation Axis to Restore Its Function in High-Risk LQT1 Variants</dc:title>
<dc:identifier>pmid:39166328</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325009</dc:identifier>
</item>
<item>
<title>Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39166327/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821180851&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our findings suggested that colchicine resulted in favorable effects on coronary plaque stabilization at optical coherence tomography in patients with acute coronary syndrome.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 21. doi: 10.1161/CIRCULATIONAHA.124.069808. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Colchicine has been approved to reduce cardiovascular risk in patients with coronary heart disease on the basis of its potential benefits demonstrated in the COLCOT (Colchicine-Optical Coherence Tomography Trial) and LoDoCo2 studies. Nevertheless, there are limited data available about the specific impact of colchicine on coronary plaques.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was a prospective, single-center, randomized, double-blind clinical trial. From May 3, 2021, until August 31, 2022, a total of 128 patients with acute coronary syndrome aged 18 to 80 years with lipid-rich plaque (lipid pool arc >;90°) detected by optical coherence tomography were included. The subjects were randomly assigned in a 1:1 ratio to receive either colchicine (0.5 mg once daily) or placebo for 12 months. The primary end point was the change in the minimal fibrous cap thickness from baseline to the 12-month follow-up.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 128 patients, 52 in the colchicine group and 52 in the placebo group completed the study. The mean age of the 128 patients was 58.0±9.8 years, and 25.0% were female. Compared with placebo, colchicine therapy significantly increased the minimal fibrous cap thickness (51.9 [95% CI, 32.8 to 71.0] μm versus 87.2 [95% CI, 69.9 to 104.5] μm; difference, 34.2 [95% CI, 9.7 to 58.6] μm; <i>P</i>=0.006), and reduced average lipid arc (-25.2° [95% CI, -30.6° to -19.9°] versus -35.7° [95% CI, -40.5° to -30.8°]; difference, -10.5° [95% CI, -17.7° to -3.4°]; <i>P</i>=0.004), mean angular extension of macrophages (-8.9° [95% CI, -13.3° to -4.6°] versus -14.0° [95% CI, -18.0° to -10.0°]; difference, -6.0° [95% CI, -11.8° to -0.2°]; <i>P</i>=0.044), high-sensitivity C-reactive protein level (geometric mean ratio, 0.6 [95% CI, 0.4 to 1.0] versus 0.3 [95% CI, 0.2 to 0.5]; difference, 0.5 [95% CI, 0.3 to 1.0]; <i>P</i>=0.046), interleukin-6 level (geometric mean ratio, 0.8 [95% CI, 0.6 to 1.1] versus 0.5 [95% CI, 0.4 to 0.7]; difference, 0.6 [95% CI, 0.4 to 0.9]; <i>P</i>=0.025), and myeloperoxidase level (geometric mean ratio, 1.0 [95% CI, 0.8 to 1.2] versus 0.8 [95% CI, 0.7 to 0.9]; difference, 0.8 [95% CI, 0.6 to 1.0]; <i>P</i>=0.047).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings suggested that colchicine resulted in favorable effects on coronary plaque stabilization at optical coherence tomography in patients with acute coronary syndrome.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04848857.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39166327/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821180851&v=2.18.0.post9+e462414">39166327</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069808>10.1161/CIRCULATIONAHA.124.069808</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39166327</guid>
<pubDate>Wed, 21 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Miao Yu</dc:creator>
<dc:creator>Yong Yang</dc:creator>
<dc:creator>Si-Lai Dong</dc:creator>
<dc:creator>Chen Zhao</dc:creator>
<dc:creator>Fen Yang</dc:creator>
<dc:creator>Yuan-Fan Yuan</dc:creator>
<dc:creator>Yu-Hua Liao</dc:creator>
<dc:creator>Shao-Lin He</dc:creator>
<dc:creator>Kun Liu</dc:creator>
<dc:creator>Fen Wei</dc:creator>
<dc:creator>Hai-Bo Jia</dc:creator>
<dc:creator>Bo Yu</dc:creator>
<dc:creator>Xiang Cheng</dc:creator>
<dc:date>2024-08-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39166327</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069808</dc:identifier>
</item>
<item>
<title>Relationship of Subendocardial Perfusion to Myocardial Injury, Cardiac Structure, and Clinical Outcomes Among Patients With Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39166326/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821180851&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among patients with hypertension without flow-limiting coronary artery disease, impaired MFR(subendo) was associated with cardiovascular risk factors, elevated cardiac biomarkers, cardiac structure, and clinical events.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 21. doi: 10.1161/CIRCULATIONAHA.123.067083. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Coronary microvascular dysfunction has been implicated in the development of hypertensive heart disease and heart failure, with subendocardial ischemia identified as a driver of sustained myocardial injury and fibrosis. We aimed to evaluate the relationships of subendocardial perfusion with cardiac injury, structure, and a composite of major adverse cardiovascular and cerebral events consisting of death, heart failure hospitalization, myocardial infarction, and stroke.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Layer-specific blood flow and myocardial flow reserve (MFR; stress/rest myocardial blood flow) were assessed by <sup>13</sup>N-ammonia perfusion positron emission tomography in consecutive patients with hypertension without flow-limiting coronary artery disease (summed stress score &lt;3) imaged at Brigham and Women's Hospital (Boston, MA) from 2015 to 2021. In this post hoc observational study, biomarkers, echocardiographic parameters, and longitudinal clinical outcomes were compared by tertiles of subendocardial MFR (MFR<sub>subendo</sub>).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 358 patients, the mean age was 70.6±12.0 years, and 53.4% were male. The median MFR<sub>subendo</sub> was 2.57 (interquartile range, 2.08-3.10), and lower MFR<sub>subendo</sub> was associated with older age, diabetes, lower renal function, greater coronary calcium burden, and higher systolic blood pressure (<i>P</i>&lt;0.05 for all). In cross-sectional multivariable regression analyses, the lowest tertile of MFR<sub>subendo</sub> was associated with myocardial injury and with greater left ventricular wall thickness and volumes compared with the highest tertile. Relative to the highest tertile, low MFR<sub>subendo</sub> was independently associated with an increased rate of major adverse cardiovascular and cerebral events (adjusted hazard ratio, 2.99 [95% CI, 1.39-6.44]; <i>P</i>=0.005) and heart failure hospitalization (adjusted hazard ratio, 2.76 [95% CI, 1.04-7.32; <i>P</i>=0.042) over 1.1 (interquartile range, 0.6-2.8) years median follow-up.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among patients with hypertension without flow-limiting coronary artery disease, impaired MFR<sub>subendo</sub> was associated with cardiovascular risk factors, elevated cardiac biomarkers, cardiac structure, and clinical events.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39166326/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821180851&v=2.18.0.post9+e462414">39166326</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067083>10.1161/CIRCULATIONAHA.123.067083</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39166326</guid>
<pubDate>Wed, 21 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Xiaolei Xu</dc:creator>
<dc:creator>Sanjay Divakaran</dc:creator>
<dc:creator>Brittany N Weber</dc:creator>
<dc:creator>Jon Hainer</dc:creator>
<dc:creator>Shelby S Laychak</dc:creator>
<dc:creator>Benjamin Auer</dc:creator>
<dc:creator>Marie F Kijewski</dc:creator>
<dc:creator>Ron Blankstein</dc:creator>
<dc:creator>Sharmila Dorbala</dc:creator>
<dc:creator>Ludovic Trinquart</dc:creator>
<dc:creator>Piotr Slomka</dc:creator>
<dc:creator>Li Zhang</dc:creator>
<dc:creator>Jenifer M Brown</dc:creator>
<dc:creator>Marcelo F Di Carli</dc:creator>
<dc:date>2024-08-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Relationship of Subendocardial Perfusion to Myocardial Injury, Cardiac Structure, and Clinical Outcomes Among Patients With Hypertension</dc:title>
<dc:identifier>pmid:39166326</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067083</dc:identifier>
</item>
<item>
<title>Effects of Sedentary Behavior Reduction on Blood Pressure in Desk Workers: Results From the RESET-BP Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39166323/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821180851&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: A 3-month intervention that decreased SB and increased standing by ≈1 hour during the work day was not effective for reducing BP. Future directions include examining effects of interventions reducing SB through activity other than work-time standing and clarifying association between standing and PWV in opposite directions for work and nonwork time.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 21. doi: 10.1161/CIRCULATIONAHA.123.068564. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Sedentary behavior (SB) is observationally associated with cardiovascular disease risk. However, randomized clinical trials testing causation are limited. We hypothesized that reducing SB would decrease blood pressure (BP) and pulse wave velocity (PWV) in sedentary adults.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This parallel-arm, 3-month randomized clinical trial recruited desk workers, age 18 to 65 years, with systolic BP 120 to 159 or diastolic BP (DBP) 80 to 99 mm Hg, off antihypertensive medications, and reporting &lt;150 min/wk of moderate to vigorous intensity physical activity. Participants were randomized to a SB reduction intervention or a no-contact control group. The intervention sought to replace 2 to 4 h/d of SB with standing and stepping through coaching, a wrist-worn activity prompter, and a sit-stand desk. SB and physical activity were measured with a thigh-worn accelerometer and quantified during all waking hours and separately during work and nonwork times. Clinic-based resting systolic BP (primary outcome) and DBP, 24-hour ambulatory BP, and PWV were assessed by blinded technicians at baseline and 3 months.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Participants (n=271) had a mean age of 45 years and systolic BP/DBP 129/83 mm Hg. Compared with controls, intervention participants had reduced SB (-1.15±0.17 h/d), increased standing (0.94±0.14 h/d), and increased stepping (5.4±2.4 min/d; all <i>P</i>&lt;0.05). SB and activity changes mainly occurred during work time and were below the goal. The intervention did not reduce BP or PWV in the intervention group compared with controls. Between-group differences in resting systolic BP and DBP changes were -0.22±0.90 (<i>P</i>=0.808) and 0.13±0.61 mm Hg (<i>P</i>=0.827), respectively. The findings were similarly null for ambulatory BP and PWV. Decreases in work-time SB were associated with favorable reductions in resting DBP (r=0.15, <i>P</i>=0.017). Contrary to our hypotheses, reductions in work-time SB (r=-0.19, <i>P</i>=0.006) and increases in work-time standing (r=0.17, <i>P</i>=0.011) were associated with unfavorable increases in carotid-femoral PWV. As expected, increases in non-work-time standing were favorably associated with carotid-femoral PWV (r=-0.14, <i>P</i>=0.038).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: A 3-month intervention that decreased SB and increased standing by ≈1 hour during the work day was not effective for reducing BP. Future directions include examining effects of interventions reducing SB through activity other than work-time standing and clarifying association between standing and PWV in opposite directions for work and nonwork time.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03307343.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39166323/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821180851&v=2.18.0.post9+e462414">39166323</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068564>10.1161/CIRCULATIONAHA.123.068564</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39166323</guid>
<pubDate>Wed, 21 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Bethany Barone Gibbs</dc:creator>
<dc:creator>Subashan Perera</dc:creator>
<dc:creator>Kimberly A Huber</dc:creator>
<dc:creator>Joshua L Paley</dc:creator>
<dc:creator>Molly B Conroy</dc:creator>
<dc:creator>John M Jakicic</dc:creator>
<dc:creator>Matthew F Muldoon</dc:creator>
<dc:date>2024-08-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Effects of Sedentary Behavior Reduction on Blood Pressure in Desk Workers: Results From the RESET-BP Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39166323</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068564</dc:identifier>
</item>
<item>
<title>Von Willebrand factor exacerbates heart failure through formation of neutrophil extracellular traps</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39165142/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821180851&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study established the role of a novel VWF-SLC44A2-NET axis in regulating mitochondrial homeostasis and function, leading to cardiac apoptosis and contributing to HF pathogenesis. Targeting this axis may offer a potential therapeutic approach for HF treatment.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 21:ehae517. doi: 10.1093/eurheartj/ehae517. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Heart failure (HF) is a leading cause of mortality worldwide and characterized by significant co-morbidities and dismal prognosis. Neutrophil extracellular traps (NETs) aggravate inflammation in various cardiovascular diseases; however, their function and mechanism of action in HF pathogenesis remain underexplored. This study aimed to investigate the involvement of a novel VWF-SLC44A2-NET axis in HF progression.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: NET levels were examined in patients with HF and mouse models of transverse aortic constriction (TAC) HF. PAD4 knockout mice and NET inhibitors (GSK-484, DNase I, NEi) were used to evaluate the role of NETs in HF. RNA sequencing was used to investigate the downstream mechanisms. Recombinant human ADAMTS13 (rhADAMTS13), ADAMTS13, and SLC44A2 knockouts were used to identify novel upstream factors of NETs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Elevated NET levels were observed in patients with HF and TAC mouse models of HF. PAD4 knockout and NET inhibitors improved the cardiac function. Mechanistically, NETs induced mitochondrial dysfunction in cardiomyocytes, inhibiting mitochondrial biogenesis via the NE-TLR4-mediated suppression of PGC-1α. Furthermore, VWF/ADAMTS13 regulated NET formation via SLC44A2. Additionally, sacubitril/valsartan amplifies the cardioprotective effects of the VWF-SLC44A2-NET axis blockade.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study established the role of a novel VWF-SLC44A2-NET axis in regulating mitochondrial homeostasis and function, leading to cardiac apoptosis and contributing to HF pathogenesis. Targeting this axis may offer a potential therapeutic approach for HF treatment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39165142/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821180851&v=2.18.0.post9+e462414">39165142</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae517>10.1093/eurheartj/ehae517</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39165142</guid>
<pubDate>Wed, 21 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Ge Mang</dc:creator>
<dc:creator>Jianfeng Chen</dc:creator>
<dc:creator>Ping Sun</dc:creator>
<dc:creator>Ruishuang Ma</dc:creator>
<dc:creator>Jingwen Du</dc:creator>
<dc:creator>Xiaoqi Wang</dc:creator>
<dc:creator>Jingxuan Cui</dc:creator>
<dc:creator>Mian Yang</dc:creator>
<dc:creator>Zhonghua Tong</dc:creator>
<dc:creator>Xiangyu Yan</dc:creator>
<dc:creator>Dongni Wang</dc:creator>
<dc:creator>Huiqi Xie</dc:creator>
<dc:creator>Yujia Chen</dc:creator>
<dc:creator>Qiannan Yang</dc:creator>
<dc:creator>Yingjin Kong</dc:creator>
<dc:creator>Jiaqi Jin</dc:creator>
<dc:creator>Jian Wu</dc:creator>
<dc:creator>Maomao Zhang</dc:creator>
<dc:creator>Bo Yu</dc:creator>
<dc:date>2024-08-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Von Willebrand factor exacerbates heart failure through formation of neutrophil extracellular traps</dc:title>
<dc:identifier>pmid:39165142</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae517</dc:identifier>
</item>
<item>
<title>Hot topics in thromboembolic risk prevention, heart failure monitoring, and cardiomyopathy risk stratification</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39164016/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821180851&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 21;45(32):2899-2903. doi: 10.1093/eurheartj/ehae522.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39164016/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821180851&v=2.18.0.post9+e462414">39164016</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae522>10.1093/eurheartj/ehae522</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39164016</guid>
<pubDate>Tue, 20 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-08-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Hot topics in thromboembolic risk prevention, heart failure monitoring, and cardiomyopathy risk stratification</dc:title>
<dc:identifier>pmid:39164016</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae522</dc:identifier>
</item>
<item>
<title>Vaginal Lactobacillus fatty acid response mechanisms reveal a metabolite-targeted strategy for bacterial vaginosis treatment</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39163861/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821180851&amp;v=2.18.0.post9+e462414
      <description>Bacterial vaginosis (BV), a common syndrome characterized by Lactobacillus-deficient vaginal microbiota, is associated with adverse health outcomes. BV often recurs after standard antibiotic therapy in part because antibiotics promote microbiota dominance by Lactobacillus iners instead of Lactobacillus crispatus, which has more beneficial health associations. Strategies to promote L. crispatus and inhibit L. iners are thus needed. We show that oleic acid (OA) and similar long-chain fatty acids...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 14:S0092-8674(24)00823-7. doi: 10.1016/j.cell.2024.07.029. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Bacterial vaginosis (BV), a common syndrome characterized by Lactobacillus-deficient vaginal microbiota, is associated with adverse health outcomes. BV often recurs after standard antibiotic therapy in part because antibiotics promote microbiota dominance by Lactobacillus iners instead of Lactobacillus crispatus, which has more beneficial health associations. Strategies to promote L. crispatus and inhibit L. iners are thus needed. We show that oleic acid (OA) and similar long-chain fatty acids simultaneously inhibit L. iners and enhance L. crispatus growth. These phenotypes require OA-inducible genes conserved in L. crispatus and related lactobacilli, including an oleate hydratase (ohyA) and putative fatty acid efflux pump (farE). FarE mediates OA resistance, while OhyA is robustly active in the vaginal microbiota and enhances bacterial fitness by biochemically sequestering OA in a derivative form only ohyA-harboring organisms can exploit. OA promotes L. crispatus dominance more effectively than antibiotics in an in vitro BV model, suggesting a metabolite-based treatment approach.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39163861/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821180851&v=2.18.0.post9+e462414">39163861</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.029>10.1016/j.cell.2024.07.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39163861</guid>
<pubDate>Tue, 20 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Meilin Zhu</dc:creator>
<dc:creator>Matthew W Frank</dc:creator>
<dc:creator>Christopher D Radka</dc:creator>
<dc:creator>Sarah Jeanfavre</dc:creator>
<dc:creator>Jiawu Xu</dc:creator>
<dc:creator>Megan W Tse</dc:creator>
<dc:creator>Julian Avila Pacheco</dc:creator>
<dc:creator>Jae Sun Kim</dc:creator>
<dc:creator>Kerry Pierce</dc:creator>
<dc:creator>Amy Deik</dc:creator>
<dc:creator>Fatima Aysha Hussain</dc:creator>
<dc:creator>Joseph Elsherbini</dc:creator>
<dc:creator>Salina Hussain</dc:creator>
<dc:creator>Nondumiso Xulu</dc:creator>
<dc:creator>Nasreen Khan</dc:creator>
<dc:creator>Vanessa Pillay</dc:creator>
<dc:creator>Caroline M Mitchell</dc:creator>
<dc:creator>Krista L Dong</dc:creator>
<dc:creator>Thumbi Ndung'u</dc:creator>
<dc:creator>Clary B Clish</dc:creator>
<dc:creator>Charles O Rock</dc:creator>
<dc:creator>Paul C Blainey</dc:creator>
<dc:creator>Seth M Bloom</dc:creator>
<dc:creator>Douglas S Kwon</dc:creator>
<dc:date>2024-08-20</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Vaginal Lactobacillus fatty acid response mechanisms reveal a metabolite-targeted strategy for bacterial vaginosis treatment</dc:title>
<dc:identifier>pmid:39163861</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.029</dc:identifier>
</item>
<item>
<title>Mining human microbiomes reveals an untapped source of peptide antibiotics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39163860/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821180851&amp;v=2.18.0.post9+e462414
      <description>Drug-resistant bacteria are outpacing traditional antibiotic discovery efforts. Here, we computationally screened 444,054 previously reported putative small protein families from 1,773 human metagenomes for antimicrobial properties, identifying 323 candidates encoded in small open reading frames (smORFs). To test our computational predictions, 78 peptides were synthesized and screened for antimicrobial activity in vitro, with 70.5% displaying antimicrobial activity. As these compounds were...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 16:S0092-8674(24)00802-X. doi: 10.1016/j.cell.2024.07.027. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Drug-resistant bacteria are outpacing traditional antibiotic discovery efforts. Here, we computationally screened 444,054 previously reported putative small protein families from 1,773 human metagenomes for antimicrobial properties, identifying 323 candidates encoded in small open reading frames (smORFs). To test our computational predictions, 78 peptides were synthesized and screened for antimicrobial activity in vitro, with 70.5% displaying antimicrobial activity. As these compounds were different compared with previously reported antimicrobial peptides, we termed them smORF-encoded peptides (SEPs). SEPs killed bacteria by targeting their membrane, synergizing with each other, and modulating gut commensals, indicating a potential role in reconfiguring microbiome communities in addition to counteracting pathogens. The lead candidates were anti-infective in both murine skin abscess and deep thigh infection models. Notably, prevotellin-2 from Prevotella copri presented activity comparable to the commonly used antibiotic polymyxin B. Our report supports the existence of hundreds of antimicrobials in the human microbiome amenable to clinical translation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39163860/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821180851&v=2.18.0.post9+e462414">39163860</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.027>10.1016/j.cell.2024.07.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39163860</guid>
<pubDate>Tue, 20 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Marcelo D T Torres</dc:creator>
<dc:creator>Erin F Brooks</dc:creator>
<dc:creator>Angela Cesaro</dc:creator>
<dc:creator>Hila Sberro</dc:creator>
<dc:creator>Matthew O Gill</dc:creator>
<dc:creator>Cosmos Nicolaou</dc:creator>
<dc:creator>Ami S Bhatt</dc:creator>
<dc:creator>Cesar de la Fuente-Nunez</dc:creator>
<dc:date>2024-08-20</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Mining human microbiomes reveals an untapped source of peptide antibiotics</dc:title>
<dc:identifier>pmid:39163860</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.027</dc:identifier>
</item>
<item>
<title>Correction to: An autoantibody profile detects Brugada syndrome and identifies abnormally expressed myocardial proteins</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39163133/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821180851&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 20:ehae395. doi: 10.1093/eurheartj/ehae395. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39163133/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821180851&v=2.18.0.post9+e462414">39163133</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae395>10.1093/eurheartj/ehae395</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39163133</guid>
<pubDate>Tue, 20 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: An autoantibody profile detects Brugada syndrome and identifies abnormally expressed myocardial proteins</dc:title>
<dc:identifier>pmid:39163133</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae395</dc:identifier>
</item>
<item>
<title>Correction to: Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39163128/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821180851&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 20:ehae243. doi: 10.1093/eurheartj/ehae243. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39163128/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821180851&v=2.18.0.post9+e462414">39163128</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae243>10.1093/eurheartj/ehae243</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39163128</guid>
<pubDate>Tue, 20 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial</dc:title>
<dc:identifier>pmid:39163128</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae243</dc:identifier>
</item>
<item>
<title>The ESC Working Group on Cellular Biology of the Heart</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39162572/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821180851&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 20:ehae017. doi: 10.1093/eurheartj/ehae017. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39162572/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821180851&v=2.18.0.post9+e462414">39162572</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae017>10.1093/eurheartj/ehae017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39162572</guid>
<pubDate>Tue, 20 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Cinzia Perrino</dc:creator>
<dc:creator>Maurizio Pesce</dc:creator>
<dc:creator>Sean M Davidson</dc:creator>
<dc:date>2024-08-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The ESC Working Group on Cellular Biology of the Heart</dc:title>
<dc:identifier>pmid:39162572</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae017</dc:identifier>
</item>
<item>
<title>Triglycerides: the past, the present, and the future</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39162355/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821180851&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 20:ehae515. doi: 10.1093/eurheartj/ehae515. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39162355/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821180851&v=2.18.0.post9+e462414">39162355</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae515>10.1093/eurheartj/ehae515</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39162355</guid>
<pubDate>Tue, 20 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Eugene Braunwald</dc:creator>
<dc:date>2024-08-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Triglycerides: the past, the present, and the future</dc:title>
<dc:identifier>pmid:39162355</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae515</dc:identifier>
</item>
<item>
<title>Randomized Crossover Trial of 2-Week Ketone Ester Treatment in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39162035/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821180851&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with T2DM and HFpEF, a 2-week oral KE treatment increased cardiac output and reduced cardiac filling pressures and ventricular stiffness. At peak exercise, KE treatment markedly decreased pulmonary capillary wedge pressure and improved pressure-flow relationship. Modulation of circulating ketone levels is a potential new treatment modality for patients with T2DM and HFpEF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20. doi: 10.1161/CIRCULATIONAHA.124.069732. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a major cause of morbidity and mortality in patients with type 2 diabetes (T2DM). Acute increases in circulating levels of ketone body 3-hydroxybutyrate have beneficial acute hemodynamic effects in patients without T2DM with chronic heart failure with reduced ejection fraction. However, the cardiovascular effects of prolonged oral ketone ester (KE) treatment in patients with T2DM and HFpEF remain unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 24 patients with T2DM and HFpEF completed a 6-week randomized, double-blind crossover study. All patients received 2 weeks of KE treatment (25 g D-ß-hydroxybutyrate-(R)-1,3-butanediol × 4 daily) and isocaloric and isovolumic placebo, separated by a 2-week washout period. At the end of each treatment period, patients underwent right heart catheterization, echocardiography, and blood samples at trough levels of intervention, and then during a 4-hour resting period after a single dose. A subsequent second dose was administered, followed by an exercise test. The primary end point was cardiac output during the 4-hour rest period.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During the 4-hour resting period, circulating 3-hydroxybutyrate levels were 10-fold higher after KE treatment (1010±56 µmol/L; <i>P</i>&lt;0.001) compared with placebo (91±55 µmol/L). Compared with placebo, KE treatment increased cardiac output by 0.2 L/min (95% CI, 0.1 to 0.3) during the 4-hour period and decreased pulmonary capillary wedge pressure at rest by 1 mm Hg (95% CI, -2 to 0) and at peak exercise by 5 mm Hg (95% CI, -9 to -1). KE treatment decreased the pressure-flow relationship (∆ pulmonary capillary wedge pressure/∆ cardiac output) significantly during exercise (<i>P</i>&lt;0.001) and increased stroke volume by 10 mL (95% CI, 0 to 20) at peak exercise. KE right-shifted the left ventricular end-diastolic pressure-volume relationship, suggestive of reduced left ventricular stiffness and improved compliance. Favorable hemodynamic responses of KE treatment were also observed in patients treated with sodium-glucose transporter-2 inhibitors and glucagon-like peptide-1 analogs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with T2DM and HFpEF, a 2-week oral KE treatment increased cardiac output and reduced cardiac filling pressures and ventricular stiffness. At peak exercise, KE treatment markedly decreased pulmonary capillary wedge pressure and improved pressure-flow relationship. Modulation of circulating ketone levels is a potential new treatment modality for patients with T2DM and HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT05236335.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39162035/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821180851&v=2.18.0.post9+e462414">39162035</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069732>10.1161/CIRCULATIONAHA.124.069732</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39162035</guid>
<pubDate>Tue, 20 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Nigopan Gopalasingam</dc:creator>
<dc:creator>Kristoffer Berg-Hansen</dc:creator>
<dc:creator>Kristian Hylleberg Christensen</dc:creator>
<dc:creator>Bertil T Ladefoged</dc:creator>
<dc:creator>Steen Hvitfeldt Poulsen</dc:creator>
<dc:creator>Mads Jønsson Andersen</dc:creator>
<dc:creator>Barry Borlaug</dc:creator>
<dc:creator>Roni Nielsen</dc:creator>
<dc:creator>Niels Møller</dc:creator>
<dc:creator>Henrik Wiggers</dc:creator>
<dc:date>2024-08-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Randomized Crossover Trial of 2-Week Ketone Ester Treatment in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction</dc:title>
<dc:identifier>pmid:39162035</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069732</dc:identifier>
</item>
<item>
<title>Correction to: Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39159229/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821180851&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20;150(8):e197. doi: 10.1161/CIR.0000000000001275. Epub 2024 Aug 19.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39159229/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821180851&v=2.18.0.post9+e462414">39159229</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001275>10.1161/CIR.0000000000001275</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39159229</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:39159229</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001275</dc:identifier>
</item>
<item>
<title>Correction to: Past, Present, and Future of CTA</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39159228/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821180851&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20;150(8):e199. doi: 10.1161/CIR.0000000000001283. Epub 2024 Aug 19.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39159228/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821180851&v=2.18.0.post9+e462414">39159228</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001283>10.1161/CIR.0000000000001283</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39159228</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Past, Present, and Future of CTA</dc:title>
<dc:identifier>pmid:39159228</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001283</dc:identifier>
</item>
<item>
<title>Correction to: 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39159227/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821180851&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20;150(8):e198. doi: 10.1161/CIR.0000000000001277. Epub 2024 Aug 19.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39159227/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821180851&v=2.18.0.post9+e462414">39159227</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001277>10.1161/CIR.0000000000001277</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39159227</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines</dc:title>
<dc:identifier>pmid:39159227</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001277</dc:identifier>
</item>





























</channel>
</rss>